WASHINGTON, Oct. 10 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, today announced that Robert G. Matheny, M.D., Chief Scientific Officer, will present data on the company's next generation ECM Technology(TM) at the annual Transcatheter Cardiovascular Therapeutics (TCT) 2008 conference in Washington, D.C. next week.
The presentation entitled "Cell Therapy Devices and Concepts: Acellular Matrix Emulsion Injections to Induce Myofibroblast Proliferation and Angiogenesis" will take place on Monday, October 13th at 1:35 p.m. EDT in room 145AB as part of the Innovative Devices and Futuristic Therapies Session.
"We are very proud to have Dr. Matheny included to present preclinical data from our next generation product within this prestigious panel," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular. "Our inclusion in this session reinforces the fact that our technology continues to gain interest and acceptance among the cardiovascular community."
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure, clearance in the U.S. for cardiac tissue repair, and is conducting preclinical studies on a number of cardiovascular applications including an emulsified, injectible form of its ECM Technology as a potential treatment for heart failure.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to regenerate damaged heart tissue. For more information visit http://www.cormatrix.com.
|SOURCE CorMatrix Cardiovascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved